<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845037</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-5453-101</org_study_id>
    <nct_id>NCT02845037</nct_id>
  </id_info>
  <brief_title>Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453</brief_title>
  <official_title>A Rising Single Oral Dose Study to Investigate the Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of BIA 5-453 after single
      oral doses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, randomised, double-blind, placebo-controlled study of single ascending doses
      in 10 sequential groups of 8 healthy young male volunteers. Within each group (n=8), 6
      volunteers were randomised to receive BIA 5-453 and the remaining 2 volunteers were
      randomised to receive placebo. A volunteer participated only in a single period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 pre-dose then at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60, and 72 hours post-dose</time_frame>
    <description>Mean BIA 5-453 plasma pharmacokinetic parameters ± SD following single doses of 2, 10, 20, 50, 100, 200, 400, 600, 900 and 1200 mg of BIA 5-453 in 10 groups of 6 healthy volunteers each</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Day 1 pre-dose then at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60, and 72 hours post-dose</time_frame>
    <description>Mean BIA 5-453 plasma pharmacokinetic parameters ± SD following single doses of 2, 10, 20, 50, 100, 200, 400, 600, 900 and 1200 mg of BIA 5-453 in 10 groups of 6 healthy volunteers each</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Day 1 pre-dose then at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60, and 72 hours post-dose</time_frame>
    <description>Mean BIA 5-453 plasma pharmacokinetic parameters ± SD following single doses of 2, 10, 20, 50, 100, 200, 400, 600, 900 and 1200 mg of BIA 5-453 in 10 groups of 6 healthy volunteers each</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the infinity (AUC0-∞)</measure>
    <time_frame>Day 1 pre-dose then at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60, and 72 hours post-dose</time_frame>
    <description>Mean BIA 5-453 plasma pharmacokinetic parameters ± SD following single doses of 2, 10, 20, 50, 100, 200, 400, 600, 900 and 1200 mg of BIA 5-453 in 10 groups of 6 healthy volunteers each</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of subjects with at least one adverse event</measure>
    <time_frame>through study completion, an average of 72 hours</time_frame>
    <description>Adverse events were continuously monitored from screening until the follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% of subjects by dose group with at least one treatment-emergent adverse event (TEAEs)</measure>
    <time_frame>through study completion, an average of 72 hours</time_frame>
    <description>Treatment emergent adverse events (TEAE) were defined as adverse events which did not exist before dosing and appeared in the 72 hours following treatment administration or which was present before administration and worsened in the 72 hours following treatment administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Day 1 pre-dose then at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60, and 72 hours post-dose</time_frame>
    <description>Mean BIA 5-453 plasma pharmacokinetic parameters ± SD following single doses of 2, 10, 20, 50, 100, 200, 400, 600, 900 and 1200 mg of BIA 5-453 in 10 groups of 6 healthy volunteers each</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hypertension</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>2 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 5-453 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 5-453</intervention_name>
    <description>BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.</description>
    <arm_group_label>2 mg or placebo</arm_group_label>
    <arm_group_label>10 mg or placebo</arm_group_label>
    <arm_group_label>20 mg or placebo</arm_group_label>
    <arm_group_label>50 mg or placebo</arm_group_label>
    <arm_group_label>100 mg or placebo</arm_group_label>
    <arm_group_label>200 mg or placebo</arm_group_label>
    <arm_group_label>400 mg or placebo</arm_group_label>
    <arm_group_label>600 mg or placebo</arm_group_label>
    <arm_group_label>900 mg or placebo</arm_group_label>
    <arm_group_label>1200 mg or placebo</arm_group_label>
    <other_name>Etamicastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).</description>
    <arm_group_label>2 mg or placebo</arm_group_label>
    <arm_group_label>10 mg or placebo</arm_group_label>
    <arm_group_label>20 mg or placebo</arm_group_label>
    <arm_group_label>50 mg or placebo</arm_group_label>
    <arm_group_label>100 mg or placebo</arm_group_label>
    <arm_group_label>200 mg or placebo</arm_group_label>
    <arm_group_label>400 mg or placebo</arm_group_label>
    <arm_group_label>600 mg or placebo</arm_group_label>
    <arm_group_label>900 mg or placebo</arm_group_label>
    <arm_group_label>1200 mg or placebo</arm_group_label>
    <other_name>Placebo Gelatine capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A signed and dated informed consent form before any study-specific screening procedure
             was performed.

          2. Aged between 18 and 45 years, inclusive.

          3. Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs and digital 12-lead
             electrocardiogram (ECG).

          4. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must
             have been able to abstain from smoking during the inpatient stay.

          5. Have a high probability for compliance with and completion of the study.

        Exclusion Criteria:

        Medical History

          1. Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g.
             childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia),
             immunologic, dermatological, haematological, neurologic, or psychiatric disease.

          2. Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before
             study day 1.

          3. History of drug abuse within 1 year before study day 1.

          4. History of alcoholism within 1 year before day 1. Consumption of more than 50 g of
             ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%]
             whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15
             g

          5. History of any clinically important drug allergy.

             Physical and Laboratory Findings

          6. An automatic ECG QTc interval reading at screening or enrolment &gt;450 ms.

          7. Positive serologic findings for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.

          8. Positive findings of urine drug screen (eg, amphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA
             [3,4-methylenedioxy-methamphetamine; ecstasy]).

             Prohibited treatments

          9. Prohibited Treatments: use of any investigational drug within 90 days or prescription
             drug within 30 days before investigational medical product (IMP) administration.

         10. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or
             soda) in excess of 6 cups per day (or equivalent), of grapefruit,
             grapefruit-containing products, or alcoholic beverages within 72 before study day -1.

         11. Use of any over-the-counter drugs including herbal supplements (except for the
             occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended
             daily allowance) within 7 days before IMP administration.

         12. Donation of blood (ie 450 ml) within 90 days before study day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Rennes</city>
        <zip>F-35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

